Contact

Preparing Your Tech Company for Sale: Key Considerations to Ensure Maximum Value

December 1, 2020
Join Plante Moran and PMCF experts for an on-demand webinar designed to help you position and prepare your technology company for a sale.

Properly preparing for the sale of your company can ensure better valuation and more options to design the exit strategy that’s right for you. Join PMCF and Plante Moran experts as they cover how COVID-19 has affected the appetite of buyers in the marketplace and key considerations to prepare your technology company for an eventual exit.

 

This webinar covers:

  • The current state of the marketplace and what buyers are looking for in technology companies.
  • The importance of business readiness planning to maximize value drivers and the characteristics of a technology company ready to “go to market”.
  • How to prepare your company to stand up to the intense scrutiny from a buyer and the risk factors that can affect your sale.
  • Common mistakes your advisors can help you avoid.

 

Panelist:

  • Adams Price, PMCF, Managing Director
  • Josh White, Plante Moran, Principal

 

Watch On Demand

More Articles

After a year defined by uneven activity and macro uncertainty, M&A momentum enters 2026 with improving financing conditions, renewed buyer confidence, and substantial capital on the sidelines, creating a more constructive environment for well-positioned middle-market distributors.

Read More

After years of volatility and transformation, the Human Capital Management (HCM) industry now finds itself navigating a landscape where geopolitical tensions and technological acceleration collide to create both unique challenges and new frontiers for growth.

Read More

From transaction volume to EBITDA multiples, key indicators for plastics M&A are trending upward as 2026 begins, according to PMCF Investment Banking Managing Director John Hart.

Read More

Thirty years ago, PMCF Investment Banking set out with a clear mission: to redefine how middle‑market businesses approach M&A.

Read More

Medtech is entering 2026 with a healthier M&A environment supported by improved financing conditions, resilient sector performance, and a more straightforward path for strategic buyers and private equity.

Read More